

SPONSORS
AGENDA MED-CHEM
AGENDA BIOLOGY
**TRACK 1 - MEDCHEM
ARTIFICIAL INTELLIGENCE / MACHINE LEARNING**
**TRACK 2 - MEDCHEM
DESIGN & CUSTOM SYNTHESIS**
**TRACK 3 - MEDCHEM
INTEGRATED DRUG DISCOVERY**
**TRACK 4 - MEDCHEM
HIT TO LEAD IDENTIFICATION**
**TRACK 5 - MEDCHEM
CHEMICAL BIOLOGY & CHEMINFORMATICS**
**TRACK 6 - MEDCHEM
DISRUPTIVE TECHNOLOGIES**
**TRACK 7 - BIOLOGY
OUTSOURCING FOR EMERGING BIOPHARMA**
**TRACK 8 - BIOLOGY
DMPK & ADME**
**TRACK 9 - BIOLOGY
IN VIVO & IN VITRO PHARMACOLOGY**
**TRACK 10 - BIOLOGY
IND- PROOF OF CONCEPT**
**TRACK 11 - BIOLOGY
STRATEGIC PARTNERSHIP & OUTSOURCING**
**TRACK 12 - BIOLOGY
TARGET VALIDATION**
2019 ATTENDEES

Click here to find out what our clients think about our Strategy Meetings

OUR UNIQUE ONLINE MEETING FORMAT

- Roundtable Discussions**
 These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.
- Personalised Agenda**
 Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.
- One-to-one Meetings**
 The most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app will allow for instant and direct messaging to organise online meetings during the dedicated time to most benefit you.
- Strategic Networking**
 Strategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

CONTRIBUTORS TO THE AGENDA



Rob Howes
 Director Discovery Biology
 AstraZeneca



Joseph Mancini
 Head of Biology, Senior Director
 adMare BioInnovations



Guy Lewy
 CSO
 Sublime Therapeutics



Laurent Audoly
 CEO & Founder
 Parthenon Therapeutics



Jascha Blobel
 CEO
 Molomics



Paul Peter Tak
 Board Director
 Sitryx Therapeutics and Levicept



Tim Sparey
 CEO
 Novintum Bioscience



Ignacio Quiles
 Vice President & Commercial
 Director - Oncology Hematolog
 GSK



PJ Moloney
 CEO
 P4ML



Asif Ahmed
 Founder
 MirZyme Therapeutics

CO-HOST



Enriching life through innovation

[VISIT WEBSITE](#)

LAXAI is a fully integrated contract research and development organization that delivers solutions in drug discovery, chemical process R&D, and GMP manufacturing for innovator pharmaceutical, Biotech, and animal health companies globally. Over the years, our focus has been on providing highly efficient scientific solutions, which has enabled us to partner on more than 20 integrated drug discovery programs and multiple medicinal chemistry focused FTE collaborations. As a result, we have delivered clinical candidates and technology platforms across diverse therapeutic areas. Further, owing to our strength in chemistry and our experience in solving complex problems, we have been engaged on a number of chemical process R&D and GMP manufacturing projects by innovator pharmaceutical companies. This experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs, and custom manufactured advanced intermediates and fine chemicals.



[VISIT WEBSITE](#)

Nanome, the first virtual reality (VR) software company to launch an immersive real-time collaboration platform for scientific discovery, is changing the way we understand and interact with science at the molecular level. The software environment allows users to visualize, modify, and simulate proteins, chemical compounds, and nucleic acids to accelerate scientific decision making. The platform facilitates effective communication of data and integrates with existing computational chemistry workflows—features that have led to the adoption of the San Diego-based company's enterprise solution by several pharmaceutical and biotech companies worldwide. For more information, visit nanome.ai



[VISIT WEBSITE](#)

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing.



[VISIT WEBSITE](#)

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India's fastest growing CDMOs, the company is investing over US \$ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.



[VISIT WEBSITE](#)

At **Proventa Talent**, we always look ahead to ensure that the service we deliver to you is second to none, both now and in the future. Proventa Talent based around our three key principles of commitment, intelligence and partnership ensures an unparalleled recruitment solution in the industry. We work with the leading talent in the field to offer a service of high quality, efficiency and transparency. In addition to this, our relationship with many organisations across the Life Sciences sector means that we are constantly developing our recruitment services to offer market-leading solutions including Contingency, Executive Search, Contract and fully integrated Recruitment Process Outsourcing to suit your short, medium and long term needs.



[VISIT WEBSITE](#)

Sygnature Discovery is a leading integrated drug discovery and pre-clinical services company. We operate fully equipped modern research facilities in Nottingham and Alderley Park, UK, housing over 300 research scientists (>80% with PhDs). Our experienced drug hunters possess all the professional skills and know-how to enable success in the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 31 drug candidates to our clients, 15 of which have subsequently entered the clinic (Phases I, II and III). To find out more about us, visit our website: www.sygnaturediscovery.com



[VISIT WEBSITE](#)

Iktos is a leading chemical research Artificial Intelligence company focusing on medicinal chemistry and de novo drug design. Iktos is developing two main innovative technologies based on deep learning: Generative Modeling, which enables to design compounds that are optimized in silico to meet all the success criteria of a small molecule drug discovery project, and Retrosynthesis Analysis, which uses a data-driven approach to predicting synthetic routes from known starting materials. Since its founding in 2016, Iktos has established ~20 collaborations with pharma and biotech companies, including Janssen, Merck KGaA, Merck & Co./MSD, Grünenthal, UCB, Leo Pharma, Orion, Ammirall, SRI International, and other undisclosed ones.



[VISIT WEBSITE](#)

At **PerkinElmer Informatics**, our focus is on redefining how labs in Pharma, Biotech, Chemicals and major academic centers embrace electronic data capture, cloud-based applications and collaborative tools to manage and analyze their data. With our cloud based collaboration solutions and powerful visual analytics platforms, critical scientific data transforms into actionable insights in an automated, predictive and scalable way. Our solutions include the industry leading ChemDraw application, robust ELN, advanced analytics powered by TIBCO® Spotfire and the Signals Platform. The cloud based PerkinElmer Signals™ platform unlocks the hidden knowledge within your scientific data whether you are working independently or collaboratively with solutions for Translational Medicine, Screening, Lead Discovery, and Biologics.

PRO-PARTNERS



ONTOFORCE

[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)











[VISIT WEBSITE](#)



[VISIT WEBSITE](#)



[VISIT WEBSITE](#)

TRACK & ROOM TIME (*E.T.)	TRACK & ROOM TIME (*B.S.T.)	01 AI & MACHINE LEARNING	02 DESIGN & CUSTOM SYNTHESIS	03 INTEGRATED DRUG DISCOVERY	04 HIT TO LEAD IDENTIFICATION	05 CHEMICAL BIOLOGY & CHEMINFORMATICS	06 DISRUPTIVE TECHNOLOGIES	
7:00 - 7:30	12:00 - 12:30			KEYNOTE PRESENTATION Digital Transformation in Pharma R & D David Gosalvez, PhD - Director, Cheminformatics Product Portfolio - PerkinElmer Informatics				
7:30 - 8:30	12:30 - 13:30	Can using AI reduce attrition rates in drug discovery? Tim Sparey - CEO Novintum Bioscience	Making the molecule design cycle a success Jascha Blobel - CEO Molomics	Activation of endogenous progenitor cells by small molecules, leading to controlled tissue repair and regeneration Mauro Marigo - Head Medicinal Chem. & Alex Müller - Head Chemoinformatics Endogena Therapeutics, Inc.			High-Throughput Screening Vs MultiOMICS PJ Moloney - CEO P4ML	
8:30 - 9:30	13:30 - 14:30	1 - 1 MEETING *13:30-13:50 B.S.T.		NETWORKING BREAK	1 - 1 MEETING *13:50-14:10 B.S.T.		1 - 1 MEETING *14:10-14:30 B.S.T.	
9:30 - 10:30	14:30 - 15:30		 Alessandro Monge - VP Buss. Ops. & Dev.	 Dr Allan Jordan - Director of Oncology	 Raghava Reddy Kethiri, PhD - CSO		 Michael Bishop - Drug Disc. Specialist	
10:30 - 12:30	15:30 - 17:30	1 - 1 MEETING *15:30-15:50 B.S.T.		1 - 1 MEETING *15:50-16:10 B.S.T.	1 - 1 MEETING *16:10-16:30 B.S.T.	1 - 1 MEETING *16:30-16:50 B.S.T.	1 - 1 MEETING *16:50-17:10 B.S.T.	1 - 1 MEETING *17:10-17:30 B.S.T.
12:30 - 13:00	17:30 - 18:00			KEYNOTE PRESENTATION Real-world implementation of AI Dan Ormsby - Senior Consultant - Dotmatics				
13:00 - 14:00	18:00 - 19:00			Accelerating translation through strategic alliances Martin Swarbrick - Associate Director Cancer Research UK Therapeutic Discovery Labs.	Hit and Lead Generation: Selection of screening sets and strategies to maximise success rates Andy Merritt - Head of Chemistry LifeArc Centre	Molecular adventures in 3D and 4D: What new ground is being opened up by cloud computing? Guy Lewy - CSO Sublime Therapeutics		
14:00 - 14:20	19:00 - 19:20	1 - 1 MEETING *19:00-19:20 B.S.T.						
14:20 - 15:20	19:20 - 20:20	Practical Advice on the Implementation of AI/ML in Drug Discovery Laurent Audoly - CEO, Founder Parthenon Therapeutics					Discovery of Disruptive Technologies Mahesh Narayanan - CEO, PepVax, Inc.; Venture Partner - Newchip	

TRACK & ROOM TIME (*E.T.)	TRACK & ROOM TIME (*B.S.T.)	07 OUTSOURCING FOR EMERGING BIOPHARMA	08 DMPK & ADME	09 IN VIVO & IN VITRO PHARMACOLOGY	10 IND- PROOF OF CONCEPT	11 STRATEGIC PARTNERSHIP & OUTSOURCING	12 TARGET VALIDATION
7:00 - 7:30	12:00 - 12:30			KEYNOTE PRESENTATION Digital Transformation in Pharma R & D David Gosalvez, PhD - Director, Cheminformatics Product Portfolio - PerkinElmer Informatics			
7:30 - 8:30	12:30 - 13:30	Covid-19 has proved that we can fast forward the development of therapeutics. How can we apply these accelerated procedures to unmet medical diseases that also have a high mortality rate? Asif Ahmed - Founder MirZyme Therapeutics			Bridging the gap between empirical drug discovery and rational drug design Matthew Fyfe - Head of Chemistry Virion Therapeutics	Enabling business goals via collaborative or commercial alliances, both moderates risk and garners reward Marc Ramis - CEO Senolytic Therapeutics	What is a validated target? Discussion on generating new targets for drug discovery Rob Howes - Director Discovery Biology AstraZeneca
8:30 - 9:30	13:30 - 14:30	1 - 1 MEETING *13:30-13:50 B.S.T.		NETWORKING BREAK	1 - 1 MEETING *13:50-14:10 B.S.T.		NETWORKING BREAK
9:30 - 10:30	14:30 - 15:30						
				Mark Bittinger, VP & Global Head of Bio.			
10:30 - 12:30	15:30 - 17:30	1 - 1 MEETING *15:30-15:50 B.S.T.		1 - 1 MEETING *15:50-16:10 B.S.T.	1 - 1 MEETING *16:10-16:30 B.S.T.	1 - 1 MEETING *16:30-16:50 B.S.T.	1 - 1 MEETING *16:50-17:10 B.S.T.
12:30 - 13:00	17:30 - 18:00			KEYNOTE PRESENTATION Real-world implementation of AI Dan Ormsby - Senior Consultant - Dotmatics			
13:00 - 14:00	18:00 - 19:00			What can we still learn from cell and animal models? Marcie Glicksman, Head of Biology EnClear Therapies	What preclinical, nonclinical, and CMC data are needed to get from an IND to a PoC? David Cipolla, VP of Research Insmad Inc	Implementing open innovation in the industry: Joining pharmaceuticals, biotechs and academia together to accelerate R&D processes. Paul Peter Tak - Board Director Sitryx Therapeutics and Levicept	
14:00 - 14:20	19:00 - 19:20	1 - 1 MEETING *19:00-19:20 B.S.T.					
14:20 - 15:20	19:20 - 20:20			Optimizing Chemical Reactions with Deep Reinforcement Learning Isabel Najera, CSO Virion Therapeutics		How to improve current alliances and gain more effective collaborations Ignacio Quiles - Vice President GSK	Validated Targets through Human Biology Joseph Mancini - Head of Bio., Sr Dir. adMare Biolnnovations



David Gosalvez, PhD
 Director, Cheminformatics
 Product Portfolio
PerkinElmer Informatics



MORNING KEYNOTE

Digital Transformation in Pharma R & D

In today's era of System Biology, assays are becoming more and more complex resulting in richer data sets for analysis. To accommodate and maximize the output of this research data, a completely different IT framework is required. In this presentation we will:

- Overview the challenges resulting from this new era of big & complex data sources
- Introduce the Signals Platform designed to address these challenges
- Highlight some examples from lead discovery, screening and translational research

TIME SLOT (*B.S.T.)

12:00 - 12:30



Dan Ormsby
 Senior Consultant
Dotmatics



AFTERNOON KEYNOTE

Real-world implementation of AI

Hear first hand from Dr Dan Ormsby and his ambitions to add a real-world implementation of AI providing routine machine learning into the Dotmatics platform

TIME SLOT (*B.S.T.)

17:30 - 18:00

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Tim Sparey
CEO
Novintum **Bioscience**

ROUNDTABLE TOPIC

Can using AI reduce attrition rates in drug discovery?

TIME SLOT (*B.S.T.)
12:30 - 13:30



Laurent Audoly
CEO & Founder
Parthenon **Therapeutics**

ROUNDTABLE TOPIC

Practical Advice on the Implementation of AI/ML in Drug Discovery

- Considerations around being a “market pull” or “tech push” company
- Discuss case studies where AI/ML has not delivered to expectations, and where it has. Metrics, outcomes.
- Fast forward 1 year from now where are the biggest opportunities. Extend to 5 years from now.

TIME SLOT (*B.S.T.)
19:20 - 20:20

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Jascha Blobel
CEO
Molomics

ROUNDTABLE TOPIC

Making the molecule design cycle a success

- What are the strength of specialists and machines in the drug design process?
- How can information/data be used to get to good lead compounds?
- What value can my collaborators and partners contribute?

TIME SLOT (*B.S.T.)
12:30 - 13:30



Alessandro Monge, PhD
VP, US Operations &
Business Development
Iktos

SPONSOR ROUNDTABLE TOPIC

Rethinking drug design and synthetic accessibility in the era of Artificial Intelligence

- What are the challenges in drug design that AI has the promise to address?
- What are the barriers, both technology-wise and operational, to the application of AI to drug discovery?
- What is the impact that AI has achieved so far and what is required to realize the full potential of AI technologies in drug design and synthetic planning?



TIME SLOT (*B.S.T.)
14:30 - 15:30

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)

TRACK 3 INTEGRATED DRUG DISCOVERY



Mauro Marigo
Head of Medicinal
Chemistry
**Endogena
Therapeutics, Inc.**



Alex Müller, PhD
Head
Chemoinformatics
**Endogena
Therapeutics, Inc.**

ROUNDTABLE TOPIC

**Activation of endogenous progenitor cells
by small molecules, leading to controlled
tissue repair and regeneration**

TIME SLOT (*B.S.T.)
12:30 - 13:30



Dr Allan Jordan
Director of Oncology
Drug Discovery
Sygnature Discovery

SPONSOR ROUNDTABLE TOPIC

**Internal vs. external drug discovery resources -
what's the most effective way to advance a project?**

- What are the pros and cons of internal vs. external drug discovery programmes?
- In what way can external resources augment internal capacity and capabilities?
- What are the key drivers for placing resources externally?
- What are the key success factors for external collaboration?
- Learning from experience - what would we do differently next time?



TIME SLOT (*B.S.T.)
14:30 - 15:30



Martin Swarbrick
Associate Director
**Cancer Research UK
Therapeutic Discovery Labs.**

ROUNDTABLE TOPIC

**Accelerating translation through
strategic alliances**

- How strategic alliances and collaborations can be a way of bridging the well-documented translational gap that exists between basic biological research and insight and clinical evaluation.

TIME SLOT (*B.S.T.)
18:00 - 19:00

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Raghava Reddy Kethiri, PhD
Chief Scientific Officer
LAXAI Life Science Pvt. Ltd.

SPONSOR ROUNDTABLE TOPIC

Role of external drug discovery services in advancing the discovery pipeline

- Provides an access to external drug discovery expertise
- Meeting the quality and productivity expectation
- Role of communication & documentation



TIME SLOT (*B.S.T.)
14:30 - 15:30



Andy Merritt
Head of Chemistry
**LifeArc Centre for
Therapeutics Discovery**

ROUNDTABLE TOPIC

Hit and Lead Generation: Selection of screening sets and strategies to maximise success rates

- SP3 count and '3D-ness' - does this impact on either fragment or hit like screening success?
- 'Protein target class' focused sets - are they all just our imagination?
- DNA encoded libraries - how big is too big?

TIME SLOT (*B.S.T.)
18:00 - 19:00

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Guy Lewy
CSO
Sublime Therapeutics

ROUNDTABLE TOPIC

**Molecular adventures in 3D and 4D:
What new ground is being opened up by
cloud computing?**

- The growing impact and variety of molecular dynamics techniques.
- Should there be more focus on next-generation molecular representations?
- Has the nature of corporate silos blinkered us to some useful possibilities for the cloud?

TIME SLOT (*B.S.T.)

18:00 - 19:00

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



PJ Moloney
CEO
P4ML

ROUNDTABLE TOPIC

High-Throughput Screening Vs MultiOMICS

TIME SLOT (*B.S.T.)
12:30 - 13:30



Michael Bishop, Ph.D.
Drug Discovery Specialist;
Ex-Director of Medicinal Chemistry of GSK
Nanome

SPONSOR ROUNDTABLE TOPIC

How Virtual Reality Can Positively Impact Global Drug Discovery Efforts

- Why are drug discovery teams in pharma and biotechs adopting VR?
- How has VR affected the global R&D around Covid-19?
- What is the future of spatial computing for drug discovery?



TIME SLOT (*B.S.T.)
14:30 - 15:30



Mahesh Narayanan
CEO - **PepVax, Inc.**;
Venture Partner - **Newchip**

ROUNDTABLE TOPIC

Discovery of Disruptive Technologies

TIME SLOT (*B.S.T.)
19:20 - 20:20

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)

TRACK 7

OUTSOURCING FOR EMERGING BIOPHARMA



Asif Ahmed
Founder
MirZyme Therapeutics

ROUNDTABLE TOPIC

Covid-19 has proved that we can fast forward the development of therapeutics. How can we apply these accelerated procedures to unmet medical diseases that also have a high mortality rate?

- Can we replicate what's been done for covid?
- Can this increase the ability to get Regulatory approval?
- What can we learn from covid moving forward and will this increase investment opportunities in early stage pharma?
- With the attention of legislators on health and wellbeing of their people, is this the best time to update the life-cycle of treatment development?

TIME SLOT (*B.S.T.)

12:30 - 13:30

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)

TRACK 9 IN VIVO & IN VITRO PHARMACOLOGY



Mark Bittinger
VP & Global Head of Biology
Sai Life Sciences

SPONSOR ROUNDTABLE TOPIC

Developing fit-for-purpose cell-based assays
for mechanistic differentiation



TIME SLOT (*B.S.T.)
14:30 - 15:30



Marcie Glicksman
Head of Biology
EnClear Therapies

ROUNDTABLE TOPIC

What can we still learn from cell and
animal models?

TIME SLOT (*B.S.T.)
18:00 - 19:00



Isabel Najera
CSO
Virion Therapeutics

ROUNDTABLE TOPIC

Optimizing Chemical Reactions with
Deep Reinforcement Learning

TIME SLOT (*B.S.T.)
19:20 - 20:20

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Matthew Fyfe
Head of Chemistry and
Intellectual Property
Sitryx Therapeutics

ROUNDTABLE TOPIC

**Bridging the gap between empirical drug
discovery and rational drug design**

TIME SLOT (*B.S.T.)
12:30 - 13:30



David Cipolla
VP of Research
Insméd Inc

ROUNDTABLE TOPIC

**What preclinical, nonclinical, and CMC data
are needed to get from an IND to a PoC?**

TIME SLOT (*B.S.T.)
18:00 - 19:00

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)

STRATEGIC PARTNERSHIP & OUTSOURCING



Marc Ramis
CEO
Senolytic Therapeutics

ROUNDTABLE TOPIC

Enabling business goals via collaborative or commercial alliances, both moderates risk and garners reward

TIME SLOT (*B.S.T.)
12:30 - 13:30



Paul Peter Tak
Board Director
**Sitryx Therapeutics and
Levcept**

ROUNDTABLE TOPIC

Implementing open innovation in the industry: Joining pharmaceuticals, biotechs and academia together to accelerate R&D processes.

TIME SLOT (*B.S.T.)
18:00 - 19:00



Ignacio Quiles
Vice President & Commercial
Director - Oncology Hematology
GSK

ROUNDTABLE TOPIC

How to improve current alliances and gain more effective collaborations

TIME SLOT (*B.S.T.)
19:20 - 20:20

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



Rob Howes
Director Discovery Biology
AstraZeneca

ROUNDTABLE TOPIC

What is a validated target?
Discussion on generating new targets
for drug discovery

TIME SLOT (*B.S.T.)
12:30 - 13:30



Joseph Mancini
Head of Biology, Senior Director
adMare BioInnovations

ROUNDTABLE TOPIC

**Validated Targets through
Human Biology**

TIME SLOT (*B.S.T.)
19:20 - 20:20

[LEARN MORE ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)

COMPANY	JOB TITLE
AB-Science	Head of Computational chemistry
ABAC Therapeutics	Chief Executive Officer & Founder
Abbvie	Senior Director, Discovery Platform Technologies
Abbvie	Head of Discovery Chemistry and Screening biology
Abbvie	Vice President and Distinguished Research Fellow, Discovery Chemistry and Technology
Almirall	Chemistry and Technology
Amcure	Section Head Medicinal Chemistry II
Annexin Pharmaceutical	Chief Executive Officer
AstraZeneca	Chief Scientific Officer and Chief Medical Officer
AstraZeneca	Vice President, Global Head of Structure, Biophysics & Fragment-Based lead Generation
Astrazeneca	Global Head Oncology Safety
Astrazeneca	Executive Director
Astrazeneca	Associate Principal Scientist
Astrazeneca	Associate Director
AstraZeneca	Lead Scientist
Astrazeneca	Senior Scientist/Lead Scientist
Astrazeneca	Senior Director, Medicinal Chemistry
Barts Clinical Trials Unit, Queen Mary University of London	Director, Medicinal Chemistry
Bayer	Vice President, Head Research Pharmacokinetics
Bayer	Director, Medicinal Chemistry
Bergenbio	CSO
Biogen	Head of Computational Chemistry
Boehringer Ingelheim RCV GmbH & Co KG	Scientific Director - Group Leader
Bridge Biotec	Director/CEO
Bridge Biotech	CEO/Director
Bridge Biotech	Head of Department of Life Sciences
Brunel University London	CSO
C4X Discovery Ltd.	VP Structural Design & Medicinal Chemistry
C4X Discovery Ltd.	VP Medicinal Chemistry
C4X Discovery Ltd.	Head of Chemistry
Centauri Therapeutics	Professor of Biomedical Science, and Head of Biomedical and Environmental Health Research
De Montfort University	Business Development & Programme Manager
E Therapeutics Plc	Principal Data Scientist
E-Therapeutics	Head of Discovery Informatics

COMPANY	JOB TITLE
Elasmogen	Chief Executive Officer and Chief Scientific Officer
Eli Lilly	Director, Emerging Technologies and Innovation
Eli Lilly	Senior Research Scientist
Forendo Pharma	Head of Drug Discovery
Geneuro	Senior Vice President, Head of Preclinical Development
GlaxoSmithKline	Senior MetaData Manager
GSK	Research Director
GSK	UK Director Structural Biology & Biophysics
GSK	VP, Mechanistic Safety
GSK	Scientific Project Leadership
GSK	Big Data Analyst
Gsk	Scientific Leader
GSK	Research Director/ Sr. Fellow
GSK	Research Director
GSK	Scientific Leader
GSK	Director, Medicinal Chemistry
Idorsia	Computational Chemist
Idorsia	Discovery Scientist & Head of Laboratory
Imperial College London	Professor of Cancer Biology
Inventiva	Head of Chemistry
Ipsen	Director - Toxins In Vitro
Ipsen	Principal Scientist
Janssen	Head, Computational Chemistry
Janssen Pharmaceutica	Computational Chemist
Johnson Johnson	Senior Director - New Ventures and Transactions
KalVista Pharmaceuticals	Director of Medicinal Chemistry
Karus Therapeutics	Chief Operations Officer & Chief Scientific Officer
Leo Pharma	Vice President of Research
LifeArc	Head of Chemistry
LifeArc	Principal Scientist
Lundbeck	Director and Head of Medicinal Chemistry
Merck	Executive Director, Global Head Quantitative Pharmacology
Merck	Director, Global Head of Search & Evaluation Discovery Technologies
Merck KGaA	Associate Director
Merck Serono	Director Discovery DMPK
Merck Sharp and Dohme	Executive Director
Mirzyme Therapeutics	ECO
MirZyme Therapeutics	Director for R&D
MirZyme Therapeutics	Senior scientist/Research Fellow

COMPANY	JOB TITLE
Novartis	Senior Investigator I
Novartis	Investigator III / Lab Head Screening Sciences
Novartis	Global Head, External Science & Drug Discovery, Global Discovery Chemistry
Novo Nordisk	Director
Novo Nordisk	Principal Data Scientist
Orion Pharma	Director, Global Medicine Design
Redx Pharma	Principal Scientist
Roche	Global Head Strategic Alliances, pRED Informatics
Roche	Head of Medicinal Chemistry
Roche Innovation Center	Large Molecule Research Digital Lead
Sanofi	Vice President, Head of North America Diabetes and Cardiovascular Scientific Communications, North America Medical Affairs
Sanofi	Director Integrated Drug Discovery Outsourcing
Sanofi	Director, External Innovation in Drug Discovery
Sanofi	Section Head Small Molecular Design
Sanofi	Head External Innovation Drug Discovery
Sentinel Oncology	Director of Chemistry
Sentinel Oncology Ltd	Director of Chemistry
Silence Therapeutics	VP, Head of Technology Innovation
Sosei Heptares	Medicinal Chemistry Director
Summit Therapeutics	Director, Chemistry
Topadur Pharma	Chief Operating Officer
Topivert Pharma	Head of Biology

COMPANY	JOB TITLE
UCB	Director, Structural Biology & Biophysics
UCB	Director (Structural Biology and New Modalities)
UCB	Principal Scientist Crystallographer
UCL	Senior Research Associate/ Lead Biologist
University of Bradford	Head of Medicinal Chemistry
University of Bristol	Professor of Organic Chemistry
University of Central Lancashire	Chairman in Biosciences
University of Geneva	Professor and Director
University of Glasgow	Professor of Chemical Biology
University of Nottingham	Professor of Developmental Physiology
University of Oxford	Medicinal Chemistry Advisor
University of Southampton	Professor, Director of Research
University of Surrey	Professor of RNA Biology
Vernalis	Research Director
Vertex	Principal Research Fellow/ Head Biological Sciences
Vertex	Head of Chemistry, UK
Vifor Pharma	Director and Head of Toxicology
Vifor Pharma	Head of Chemical and Preclinical